- Home
- XGN vs MCRB Comparison
XGN vs MCRB Comparison
Compare XGN & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | XGN | MCRB |
|---|---|---|
| Founded | 2002 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 138.0M | 140.7M |
| IPO Year | 2019 | 2015 |
Fundamental Metrics
Financial Performance| Metric | XGN | MCRB |
|---|---|---|
| Price | $4.72 | $15.93 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 6 | 3 |
| Target Price | $13.67 | ★ $14.33 |
| AVG Volume (30 Days) | ★ 546.8K | 56.4K |
| Earning Date | 03-10-2026 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.62 |
| Revenue | ★ $63,599,000.00 | $351,000.00 |
| Revenue This Year | $21.76 | N/A |
| Revenue Next Year | $15.63 | N/A |
| P/E Ratio | ★ N/A | $25.78 |
| Revenue Growth | ★ 14.08 | N/A |
| 52 Week Low | $2.67 | $6.53 |
| 52 Week High | $12.23 | $29.98 |
Technical Indicators
Market Signals| Indicator | XGN | MCRB |
|---|---|---|
| Relative Strength Index (RSI) | 20.50 | 51.27 |
| Support Level | $4.75 | $15.00 |
| Resistance Level | $6.75 | $16.42 |
| Average True Range (ATR) | 0.42 | 0.85 |
| MACD | -0.06 | 0.16 |
| Stochastic Oscillator | 0.24 | 82.99 |
Price Performance
Historical ComparisonAbout XGN Exagen Inc.
Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.